A detailed history of Vanguard Group Inc transactions in Foghorn Therapeutics Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,059,485 shares of FHTX stock, worth $8.55 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,059,485
Previous 1,102,493 3.9%
Holding current value
$8.55 Million
Previous $7.4 Million 17.64%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$5.05 - $8.0 $217,190 - $344,064
-43,008 Reduced 3.9%
1,059,485 $6.09 Million
Q1 2024

May 10, 2024

BUY
$2.82 - $7.94 $218,211 - $614,397
77,380 Added 7.55%
1,102,493 $7.4 Million
Q4 2023

Feb 14, 2024

BUY
$2.94 - $6.76 $18,915 - $43,493
6,434 Added 0.63%
1,025,113 $6.61 Million
Q3 2023

Nov 14, 2023

BUY
$5.0 - $9.87 $18,710 - $36,933
3,742 Added 0.37%
1,018,679 $5.09 Million
Q2 2023

Aug 14, 2023

SELL
$5.37 - $8.84 $37,740 - $62,127
-7,028 Reduced 0.69%
1,014,937 $7.15 Million
Q1 2023

May 15, 2023

BUY
$4.66 - $8.99 $18,998 - $36,652
4,077 Added 0.4%
1,021,965 $6.34 Million
Q4 2022

Feb 10, 2023

BUY
$5.44 - $9.46 $27,015 - $46,978
4,966 Added 0.49%
1,017,888 $6.49 Million
Q3 2022

Nov 14, 2022

BUY
$7.52 - $18.01 $40,104 - $96,047
5,333 Added 0.53%
1,012,922 $8.69 Million
Q2 2022

Aug 12, 2022

BUY
$8.48 - $16.84 $1.25 Million - $2.47 Million
146,819 Added 17.06%
1,007,589 $13.7 Million
Q1 2022

May 13, 2022

BUY
$8.87 - $22.1 $142,620 - $355,345
16,079 Added 1.9%
860,770 $13.1 Million
Q4 2021

Feb 14, 2022

BUY
$10.79 - $22.87 $51,511 - $109,181
4,774 Added 0.57%
844,691 $19.3 Million
Q3 2021

Nov 12, 2021

BUY
$8.33 - $15.02 $1.3 Million - $2.35 Million
156,139 Added 22.83%
839,917 $11.7 Million
Q2 2021

Aug 13, 2021

BUY
$9.32 - $13.26 $6.37 Million - $9.07 Million
683,778 New
683,778 $7.3 Million

Others Institutions Holding FHTX

About Foghorn Therapeutics Inc.


  • Ticker FHTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,637,400
  • Market Cap $336M
  • Description
  • Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...
More about FHTX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.